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Abstract
On 16 and 17 July 2010, immediately prior to the XVIII International AIDS Conference in Vienna, Austria, the
International AIDS Society held a workshop on the important topic of moving beyond antiretroviral therapy and
addressing HIV persistence. “Towards a Cure: HIV Reservoirs and Strategies to Control Them” was chaired by Nobel
laureate Françoise Barré-Sinoussi and co-sponsored by the French National Agency for Research on AIDS and Viral
Hepatitis, Bundesministerium für Wissenschaft und Forschung, the National Institutes of Health, Sidaction and the
Treatment Action Group. This article gives an overview of the findings presented at the workshop; complete
abstracts are included in this supplement to the Journal of the International AIDS Society.
Introduction
The availability of antiretroviral therapies (ART) capable
of prolonged suppression of HIV replication has drama-
tically altered the AIDS research landscape. The aim of
the workshop, “Towards a Cure: HIV Reservoirs and
Strategies to Control Them”, was to invigorate efforts to
move beyond ART, either by eradicating the virus (steri-
lizing cure) or by achieving long-term remission in the
absence of ongoing therapy (functional cure). The orga-
nizers placed a particular focus on encouraging young
investigators to work on this critically important topic,
with the secondary aim of improving the breadth and
quality of scientific presentations in the biomedical and
pre-clinical field at the XVIII International AIDS Con-
ference (abstracts for the workshop were selected from
submissions to the conference).
Workshop attendees represented a broad array of sta-
keholders, including basic and clinical researchers,
research funders, policymakers, community advocates
and journalists. The agenda over the two days was
apportioned into discrete sections, each addressing a dif-
ferent sub-topic; these divisions are mirrored in the sub-
heads of this report.
Main text
Clinical implications of HIV persistence during therapy
Steven Deeks from the University of California at San
Francisco (UCSF), USA, opened the meeting with a clin-
ical perspective on HIV persistence. Deeks cited evi-
dence that more than 80% of individuals on suppressive
ART have persistent low-level viremia [1]. Levels of
inflammatory biomarkers are also higher in treated
HIV-positive people compared with their HIV-negative
counterparts [2] and linked to an increased risk of mor-
bidity and mortality [3]. Deeks described how the gut is
a key site of HIV persistence, with levels of HIV DNA
approximately three to nine times higher than other
locations in the body [4]; a correlation has also been
reported between the size of the viral reservoir in the
gut and the proportion of activated CD8 T cells [5].
Taken together, Deeks noted, these data raise the
question of whether persistent HIV replication causes
immune activation and inflammation. However, several
studies have been conducted involving intensification of
antiretroviral therapy, and in all but one case [6], there
was no measurable impact on persistent viremia or mar-
kers of immune activation [7-9]. Deeks’s conclusion is
that “the simple pathway probably is not happening”.
Further evidence comes from looking at the specific
example of vascular health as a surrogate for “non-
AIDS” morbidities, such as cardiovascular disease; Deeks
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showed data from his colleague, Hiroyu Hatano, indicat-
ing no correlation between HIV DNA or RNA levels
and vascular dysfunction. In contrast, correlations
between T cell activation and vascular dysfunction have
been reported [10].
Deeks then reversed his previous question, and asked
whether inflammation and immune activation contribute
to HIV persistence. In this case, he suggested the answer
is yes: there is published evidence that lower CD4
counts are associated with increased T cell turnover and
higher frequencies of infected cells; this type of T cell
proliferation is referred to as “homeostatic” [11]. Data
also suggest that immune activation provides more acti-
vated CD4 T cell targets for HIV [12].
Deeks closed his talk with some preliminary results
from his group showing that higher levels of HIV-speci-
fic CD8 T cell responses in the gut are associated with
lower levels of HIV DNA, perhaps indicating that bol-
stering antiviral immune responses could be one way of
interrupting the ongoing cycle of immune activation and
viral infection that sustains the HIV reservoir.
Where and what are viral reservoirs? HIV-1 reservoirs and
sanctuary sites
Satya Dandekar from the University of California at
Davis, USA, provided an overview talk on the location
of HIV reservoirs in the body. Dandekar highlighted two
overarching issues: the types of cells that are infected;
and their anatomic locations. The major cell types
include CD4 T cells, monocyte/macrophages, hemato-
poietic progenitor cells and microglial cells; the gut and
brain represent the main anatomic locations. Dandekar
noted that the gut and brain share certain features,
including inaccessibility to drugs and increased numbers
of activated immune cells. Importantly, HIV reservoirs
in these locations are established early in primary infec-
tion. Dandekar suggested that the SIV/macaque model
can be used to address a number of questions relating
to viral persistence, including the role of early ART, the
effect of strategies to improve gut mucosal integrity, and
the efficacy of approaches designed to enhance virus-
specific immunity, such as therapeutic vaccines.
Five oral abstracts were presented in this workshop
session; in concordance with Dandekar’s talk, three
focused on HIV reservoirs in the gut, while the other
two evaluated infection in the brain. Joseph Wong from
UCSF showed data indicating that the activation status
and the proportions of different memory CD4 T cell
subsets varies across gut sites, and this may explain his
group’s finding that the terminal ileum is a site of
ongoing viral replication in individuals lacking detect-
able HIV RNA elsewhere (Figure 1) [4,13].
John Zaunders from St Vincent’s Hospital in Sydney,
Australia, studied peripheral blood CD4 T cells in order
to assess whether expression of the gut-homing marker,
integrin ß7, was associated with higher levels of infec-
tion (measured by HIV DNA). While HIV DNA could
be found in some CD4 T cells expressing ß7, the major-
ity of infected cells did not express the marker. Zaun-
ders concluded that most HIV DNA-containing CD4 T
cells in the peripheral blood were not activated and
infected in the gut [14].
Melissa Churchill from the Burnet Institute in Mel-
bourne, Australia, measured the extent of astrocyte
infection in the post-mortem brain tissue of individuals
with varying histories of HIV-associated encephalitis
(HIVE) and/or dementia (HAD). Churchill noted that
astrocyte infection has been described as rare in the lit-
erature [15] and is also the subject of some controversy.
Combining laser capture and single-cell microdissection
with sensitive Alu-PCR, Churchill was able to find inte-
grated HIV-DNA in astrocytes and uncovered a signifi-
cant correlation with both HAD and the severity of
HIVE. In some cases, close to 20% of astrocytes in the
deep white matter were infected with HIV, significantly
more than in previous reports.
Ronald Swanstrom from the University of North Caro-
lina at Chapel Hill, USA, highlighted the appearance of
macrophage-tropic viruses at late stages of the disease,
which are compartmentalized in the central nervous sys-
tem [16]. Swanstrom posited that the emergence of
these viruses may be another example of HIV expanding
its host cell range over the course of infection.
What are the mechanisms of persistence?
Eric Verdin from UCSF led the workshop session on the
molecular mechanisms involved in HIV latency and per-
sistence. Verdin reviewed an array of mechanisms that
can silence the transcription of HIV DNA leading to the
establishment of latency. The process is multifactorial
and involves the absence of key transcription factors
(e.g., NF-kB, NF-AT, STAT5, P-TEFb), recruitment of
chromatin modifiers (e.g., HDACs) and DNA methyla-
tion. All of these factors can conspire to repress HIV
DNA transcription.
Verdin noted that latency is likely to be heterogeneous
because different factors can act at different sites of viral
integration, and this suggests that therapeutic strategies
aiming to reduce the HIV reservoir will need to com-
bine multiple different approaches. However, methyla-
tion of the HIV genome is common in a large fraction
of latently infected cells, and inhibitors of methylation
potently synergize with trans-acting factors, such as
TNF and prostratin, to reactivate latent HIV in vitro.
Verdin closed by suggesting that future efforts will need
to focus more on mechanisms of latency in primary
lymphoid cells taken directly from HIV-positive indivi-
duals and/or in model systems that better replicate the
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in vivo situation than standard cell lines. Three presen-
tations followed that described different factors involved
in the regulation of latency, including CTIP2 and
P-TEFb [17-19].
Tae-Wook Chun from the National Institute of
Allergy and Infectious Diseases, USA, offered a sobering
case report highlighting the difficulty of addressing HIV
persistence. Chun described an individual who had been
on suppressive ART for 10.5 years and in whom quanti-
tative co-culture could only detect one infected cell out
of 1.6 billion CD4 T cells, the lowest level Chun has
ever seen. But when ART was stopped, there was only a
40-day delay in viral rebound. Chun went on to argue
that persistent, ongoing HIV replication in sanctuary
sites like the gut (as indicated in Joseph Wong’s study)
may have a greater role in sustaining viral reservoirs
than is currently assumed.
The first day of the workshop closed with a discussion
of an increasingly famous but anonymous individual
who appears to have been functionally cured of HIV
infection. Haematologist Gero Hütter provided an
update on the published case report [20]; after three
years of follow up without ART, HIV can still not be
detected in blood or tissues, and the CD4 count has
reached the highest level since the original diagnosis.
Because the individual’s treatment involved a bone mar-
row transplant necessitated by acute myelogenous leuke-
mia, there was widespread agreement that the result
cannot easily be translated into a therapeutic approach
for broader use. However, it is being viewed as a valu-
able proof of concept that a cure for HIV infection is
achievable.
What is the role of the immune system in HIV
persistence?
Brigitte Autran from the Université Pierre et Marie
Curie in Paris, France, outlined what she described as
the yang (bad) and yin (good) of HIV-specific immune
responses, noting that in some circumstances, HIV-spe-
cific CD4 T cells can become targets for virus infection,
while in others these responses are associated with
immunological control of HIV replication. Autran
Figure 1 The others in the ileum. Joseph Wong identified an unusual subset of CD45RO+ CCR7+ CD27- “other memory” CD4 T cells in the
ileum of HIV-positive individuals that may be linked to cryptic viral replication in this compartment. This slide was presented by Joseph Wong at
the workshop “Towards a Cure: HIV Reservoirs and Strategies to Control Them”.
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highlighted work by Benjamin Descours (presented later
in the same session) showing that among individuals
with the protective HLA alleles, B*27 and B*57, Gag-
specific CD8 T cell responses correlate negatively with
the size of the HIV reservoir in central memory CD4 T
cells. Autran is involved in two studies, Eramune 01 &
02, which will evaluate whether the addition of thera-
peutic vaccination or the cytokine IL-7 to intensified
ART can reduce the size of the HIV reservoir.
Five oral abstract presentations covered different
aspects of the interaction between the immune system
and HIV persistence. Vicente Planelles from the Univer-
sity of Utah, USA showed data supporting the sugges-
tion by Nicolas Chomont [11] that memory CD4 T cells
containing HIV DNA can undergo homeostatic prolif-
eration and thus increase the number of latently
infected cells [21]. Based on a suite of in vitro studies,
Vanessa Evans from Monash University in Victoria,
Australia, made the case that myeloid dendritic cells can
induce HIV latency in non-proliferating CD4 T cells
[22]. Mathias Lichterfeld from Massachusetts General
Hospital in Boston, USA, presented new data suggesting
that the CD4 T cells of elite controllers may be better
able to resist HIV infection due to greater expression of
a host protein, called p21.
What host factors are at play?
Paul de Bakker from Harvard University, USA, gave an
introduction to genetics studies and the role that they
can play in HIV research. Approaches vary depending
on the frequency of a given genetic variation in the
population. To date, study results have identified several
consistent associations with control of HIV replication
within the MHC region on chromosome six of the
human genome, but no other novel gene candidates
have emerged. De Bakker cited a recently published ana-
lysis of 2500 HIV-positive individuals that failed to repli-
cate many of the isolated reports of genetic associations
that have appeared in the literature [23]. Future studies
will need large, diverse cohorts of individuals with well-
defined phenotypes, de Bakker suggested.
Oral abstract presentations focused on host cell pro-
teins involved in viral replication, including Tetherin
[24], rhTRIM5a [25] and LEDGF/p75 [26]. Claudio
Casoli from Università degli Studi di Milano, Milan,
Italy, also presented results suggesting that HIV infec-
tion modulates expression of host cell micro-RNAs [27].
What are potential therapeutic interventions and how to
evaluate them?
The task of giving an overview of therapeutic issues fell
to Frank Maldarelli from the National Cancer Institute,
USA. Maldarelli described the “single copy” assay devel-
oped by Sarah Palmer that can measure down to one
copy of HIV RNA in three milliliters of plasma. Maldar-
elli’s group has used the assay to show that there is
persistent low-level viremia in most individuals on treat-
ment that is independent of the specific antiretroviral
regimen they are using. The level of persistent viremia
is stable over long-term follow up, and is correlated
with pre-treatment viral load. Maldarelli echoed Steve
Deeks’s review of the results of ART intensification stu-
dies, noting that most had shown no effect. The critical
test of any protocol aiming for HIV eradication,
Maldarelli argued, will be to monitor what happens after
ART is interrupted.
Among the oral abstract presentations, Carolina
Garrido from Hospital Carlos III, Madrid, Spain,
reported an unexpected impact of the integrase inhibitor
raltegravir on thymopoiesis (the production of new
naïve T cells by the thymus) [28]. The mechanism for
the effect is unclear, although there is a published report
that integrase inhibition could impact T cell gene rear-
rangements that occur in the thymus due to interference
with RAG1/2 recombinase [29].
Carolina Gutiérrez from Hospital Ramón y Cajal,
Madrid, Spain, presented a very small, nine-person
study of ART intensification with the CCR5 inhibitor
maraviroc. The results suggested some reduction in the
number of HIV-infected cells; however, there was also
an unexpected increase in 2-LTR circular DNA and
HIV RNA (measured by the Sarah Palmer single copy
assay) in some participants [30]. Larger studies will be
needed to confirm these findings.
Sandrina Da Fonseca from the Vaccine and Gene
Therapy Institute, Florida, USA, outlined the potential
utility of a cellular marker, named PD-1, in identifying
memory CD4 T cells harbouring HIV. Da Fonseca also
showed that inhibiting PD-1 may awaken the latent viral
genomes in these cells, potentially offering a new
method for depleting the HIV reservoir (Figure 2) [31].
Una O’Doherty from the University of Pennsylvania,
USA, revealed a new and potentially important method
for the measurement of residual viral replication in indivi-
duals on ART. The approach compares total levels of HIV
DNA with the amount of integrated HIV DNA in order to
quantify non-integrated proviral DNA. O’Doherty showed
that around two-thirds of people on suppressive ART
sporadically display an excess of non-integrated proviral
DNA, strongly suggesting that viral replication cycles
sometimes occur despite ART (Figure 3) [32].
Switching to the SIV/macaque model, Andrea Savar-
ino from Istituto Superiore di Sanità, Rome, Italy, stu-
died the gold-based compound auranofin (Gar1041)
which induces downregulation of the CD27 molecule on
central memory CD4 T cells, thereby potentially redu-
cing the latent HIV reservoir in this cell type. Savarino
observed a significant decay in proviral SIV DNA when
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Figure 2 Prodding HIV out of latency via PD-1. Sandrina Da Fonseca showed that blocking the PD-1 pathway induced HIV production by
latently infected CD4 T cells, suggesting PD-1 inhibition could contribute to the depletion of the HIV reservoir. This slide was presented by
Sandrina Da Fonseca at the workshop “Towards a Cure: HIV Reservoirs and Strategies to Control Them”.
Figure 3 Flickering embers of infection. Una O’Doherty reported that some individuals on HAART show sporadic excesses of non-integrated
HIV DNA, suggestive of intermittent episodes of viral replication. This slide was presented by Una O’Doherty at the workshop “Towards a Cure:
HIV Reservoirs and Strategies to Control Them”.
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Gar1041 was administered to macaques infected with
SIVmac251 and treated with intensified ART. There was
also evidence of delayed viral rebound and improved
immune control of SIV replication when ART was
stopped [33].
Closing session – eradication versus remission: is
eradication possible?
The workshop closed with two presentations addressing
broader issues related to the search for a cure. Sharon
Lewin from Monash University in Victoria, Australia,
provided context on the limitations of ART, citing data
from the Danish HIV cohort showing that, while vastly
improved, life expectancy for HIV-positive individuals
has yet to reach that of their HIV-negative counterparts
[34]. ART is also encumbered by side effects that can
significantly impinge on an individual’s quality of life,
particularly over the long term.
Lewin also pointed out that because the number of new
HIV infections continues to outpace the number of peo-
ple starting ART by 5:2, the resources needed to treat
everyone will eventually become impossibly gargantuan.
Lewin spoke eloquently of the need to engage affected
communities in HIV persistence research, highlighting
the invasive procedures required by some studies and
emphasizing the importance of translating scientific lan-
guage into more accessible terms. Finding a cure for HIV
infection, Lewin concluded, is a human rights issue.
Daria Hazuda from Merck & Co, Inc, USA, provided a
perspective from the pharmaceutical industry, offering
insights into the daunting logistical challenges of the
drug discovery process. Hazuda cited a 2003 study esti-
mating that for every 5000 to 10,000 compounds
synthesized for in vitro evaluations, approximately 250
are selected for further preclinical investigation in cellu-
lar and animal models. Of these, an average of five com-
pounds move into clinical trials and only one obtains
FDA approval [35].
Hazuda noted that the search for drugs aiming to
reverse HIV latency offers additional challenges as there
are a variety of cellular models available and results may
not always be compatible from one system to the next.
Merck has developed a high throughput assay to identify
compounds that can activate latent HIV, focusing parti-
cularly on histone deacetylase (HDAC) inhibitors.
Hazuda also described the potential advantages of
synergy between compounds, such as HDAC inhibitors
and protein kinase C (PKC) activators (e.g., prostatin).
Hazuda cited an unpublished study by Paul Luciw that
found that this combination could reduce tissue levels
of viral DNA in ART-treated macaques infected with a
simian immunodeficiency virus containing HIV reverse-
transcriptase (SHIV-RT); however, there was no delay in
viral rebound when ART was interrupted.
Hazuda concluded with some questions that need to
be addressed for the field to move forward, such as
which animal model is best, what criteria will be used to
justify human trials of new approaches, and the indica-
tors that might be used to trigger the interruption of
ART in order to judge whether an approach has worked.
Conclusions
“Towards a Cure: HIV Reservoirs and Strategies to Con-
trol Them” offered a preliminary mapping of the diffi-
cult terrain that must be navigated if a cure for HIV
infection is to be achieved. Further work is clearly
required to provide a more detailed topography, as cer-
tain fundamental issues, such as the possible contribu-
tion of localized viral replication to persistence and the
exact nature of viral sanctuary sites, remain to be
clarified.
The importance of translational clinical research invol-
ving potential therapeutic approaches emerged as a key
theme, as this work can shed light on the uncertainties
that still lurk amid the basic science. Workshop chair
and International AIDS Society (IAS) President-Elect
Françoise Barré-Sinoussi made it clear that the topic is a
key priority for the IAS, and the dialogue and exchange
of ideas begun in Vienna will continue until the journey
towards a cure is completed.
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